FLAURA/FLAURA2 Regimens as Treatment Options for NSCLC
The discussion on NSCLC narrowed in on findings out of recent clinical trials, particularly involving a combination regimen of osimertinib and chemotherapy.
CAR T-Cell Therapy Debate in Leukemia/Lymphoma Subtypes
A Satellite Sessions event that took place at Fred Hutchinson Cancer Center and discussed treatments surrounding LCL and CLL.
Integrating Acalabrutinib Plus Bendamustine/Rituximab in the Frontline MCL Treatment Protocol
Brad S. Kahl, MD, and Tycel Phillips, MD, discussed the use of acalabrutinib plus bendamustine and rituximab for patients with untreated MCL.
Appropriately De-Escalating Talquetamab to Monthly Dosing in Multiple Myeloma
An unusual patient case was presented during a Frontline Forum where experts worked through how to appropriately treat a patient who was having consistent fevers and pain.
Afatinib/Osimertinib Treatment Combinations in EGFR-Mutated Advanced NSCLC
As part of a Satellite Sessions program focused on the Cleveland Clinic and surrounding institutions, CancerNetwork hosted a panel discussion on treatment options for patients with EGFR-mutated NSCLC.
CAR T-Cell Therapy Is a Desirable Option in Second-Line Multiple Myeloma
During the 2024 IMS Annual Meeting, colleagues gathered to discuss the latest advancements in multiple myeloma.
Discussing, Managing, and Treating HER2+ Breast Cancer From the Patient’s Perspective
In a From All Angles program, a patient and her treating physician spoke about the initial diagnosis, care coordination, communication, and the adverse effects observed.
Longer Follow-Up Data Maintain Lasting Responses With Amivantamab/ Lazertinib in EGFR-Mutant NSCLC
Joshua K. Sabari, MD, and Sandip P. Patel, MD, discussed long-term findings from the phase 3 MARIPOSA trial.
Identifying HER2 Mutations for T-DXd Use in NSCLC
The Oncology Brothers spoke with Benjamin P. Levy, MD, regarding treatment updates for patients with NSCLC with HER2 expression.
Experts Discuss Choosing Bispecifics and Sequencing Options in Multiple Myeloma
During the 2024 IMS conference, teams from Cleveland, Ohio, and New York, New York, met to debate the latest advances in multiple myeloma.
